Skip to content

Bio-Rad Laboratories, Inc. BIO.B Goodwill — Total Assets

Discontinued — last reported Q4 '15

Similar metrics at other companies

Bruker logo
BRKRVarious — Goodwill
$68.6M
ResMed logo
RMDGoodwill on acquisition
$18.94M
IR
IRBiopharma — Goodwill
$816.6M
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Goodwill
$3B-0.1%
Aramark logo
ARMKReportable Legal Entities — Goodwill
$4.7B-1.0%
Equitable Holdings logo
EQHGoodwill and other intangible assets, net

Other financials

Income statement

See full
Revenue$592.1M+1.1%
Gross profit$309.4M+1.1%
Operating income$34.1M+43.9%
Net income-$527.1M-924%
EPS (diluted)-$19.55-954%

Balance sheet

See full
Cash & equivalents$509.0M-2.7%
Total debt$987.3M-28.4%
Total equity$6.9B+2.6%
Total assets$9.8B+2.8%

Cash flow

See full
Operating cash flow$108.1M-16.8%
CapEx$30.0M-12.8%
Free cash flow$78.1M-18.2%

Valuation

See full
Market cap$7.56B+10.3%
Enterprise value$8.04B+4.2%
P/E44.8×
P/S2.9×+0.2×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin8.8%-3.1pp
Net margin6.5%+3.4pp
FCF margin13.8%-0.2pp

Returns & leverage

See full
Return on equity2.5%+1.3pp
Debt / equity0.1×-0.1×
Current ratio3.2×-2.8×

Where this comes from

Reported directly by Bio-Rad Laboratories, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Bio-Rad Laboratories, Inc.’s 10-K, filed February 29, 2016, on SEC EDGAR. View the filing →

Questions, answered.

What does goodwill — total assets mean?
The value of intangible assets like brand and customer base acquired through past company purchases.
How do you interpret goodwill — total assets?
An increase typically indicates recent acquisition activity, while a decrease may signal impairment charges or divestitures. High levels relative to total assets suggest a reliance on inorganic growth and potential sensitivity to future write-downs.
How does goodwill — total assets compare across companies?
Peers in the life sciences and diagnostics sectors often carry significant goodwill due to frequent M&A activity aimed at acquiring new technologies or market share.